Monitor next quarter's CyPath Lung test volume and cash burn trajectory. The June offering provides near-term liquidity but dilution and delisting risk cap upside. A reverse stock split or additional financing may be needed to maintain Nasdaq listing.
Price Chart
Executive Summary
bioAffinity Technologies reported Q2 2026 revenue of $1.5M (+19% YoY) and a net loss of $3.4M (improved from $4.1M), driven by 216% YoY growth in CyPath Lung test volume. However, cash burned to $2.4M, a dilutive June offering increased shares by 51%, and the company faces Nasdaq delisting risk, creating a mixed outlook.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $1,510,579, up 19% from $1,269,483 in Q2 2025
- CyPath Lung test volume increased 216% year-over-year in Q2 2026
- Net loss improved to $3,366,082 from $4,060,787 in Q2 2025
- Cash and equivalents $2.4M as of June 30, 2026, down from $6.4M at Dec 31, 2025
- June 2026 public offering raised ~$3.2M gross proceeds; shares outstanding rose 51% to 6,783,061
- Company disclosed receipt of a Nasdaq delisting determination notice in forward-looking statements
Financial Impact
Revenue growth of 19% YoY to $1.5M; net loss narrowed by 17% to $3.4M; cash burn rate ~$1.2M per month
Risk Factors
- Cash runway likely less than 2 quarters at current burn rate without additional financing
- Nasdaq delisting risk could force reverse split or further dilution
- Significant shareholder dilution from June offering (51% increase in shares outstanding)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-036486 |
| Document: form8-k.htm | 0001493152-26-036486 |
| Document: 0001493152-26-036486-index-headers.html | 0001493152-26-036486 |
| Document: 0001493152-26-036486-index.html | 0001493152-26-036486 |
| Document: 0001493152-26-036486.txt | 0001493152-26-036486 |
| 8-K Data (Synthetic) | 0001493152-26-036486 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | DEF 14A | $2.81 | awaiting T+1 | — | $2.83 (+0.71%) |
Oct 15, 2026 11d ago | 8-K | $3.96 $3.73 | ▼ −5.81% | ▼ −4.70% | $2.83 (−28.54%) |
Oct 13, 2026 13d ago | 8-K | $3.63 $3.56 | ▼ −1.79% | ▼ −0.71% | $2.83 (−21.93%) |
Oct 9, 2026 17d ago | 8-K | $3.90 $3.63 | ▲ +7.05% | ▲ +7.04% | $2.83 (+27.44%) |
Oct 9, 2026 17d ago | 424B5 | $4.73 $3.90 | ▲ +17.46% | ▲ +17.40% | $2.83 (+40.11%) |
Oct 9, 2026 17d ago | 424B5 | $4.73 $3.90 | ▼ −17.46% | ▼ −17.40% | $2.83 (−40.11%) |
Oct 8, 2026 18d ago | 8-K | $5.64 $4.73 | ▼ −16.22% | ▼ −16.82% | $2.83 (−49.82%) |
Oct 6, 2026 20d ago | 8-K | $6.06 $6.16 | ▲ +1.65% | ▲ +1.89% | $2.83 (−53.30%) |
Sep 30, 2026 26d ago | 8-K | $6.56 $6.15 | ▼ −6.33% | ▼ −6.50% | $2.83 (−56.86%) |
Sep 22, 2026 4w ago | 8-K | $8.56 $7.94 | ▼ −7.19% | ▼ −6.47% | $2.83 (−66.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers